

Please replace the paragraph bridging pages 22-23 with the following:

--The cleavage sites, targeting *gag* and *pol*, with the essential GUX triplet (where X is any nucleotide base) are as follows:

A2

GAG 1	5' UAGUAGAAUGUAUAGCCCUAC (SEQ ID NO: 16)
GAG 2	5' AACCCAGAUUGUAAGACUAUUU (SEQ ID NO: 17)
GAG 3	5' UGUUCAAUUGUGGCAAAGAAG (SEQ ID NO: 18)
GAG 4	5' AAAAAGGGCUGUUGGAAAUGUG (SEQ ID NO: 19)
POL 1	5' ACGACCCCUUCGUCACAAUAAAG (SEQ ID NO: 20)
POL 2	5' GGAAUUGGAGGUUUUAUCAAAG (SEQ ID NO: 21)
POL 3	5' AUAUUUUUCAGUUCUUAGAU (SEQ ID NO: 22)
POL 4	5' UGGAUGAUUUGUAUGUAGGAUC (SEQ ID NO: 23)
POL 5	5' CUUUGGAUGGGUUAUGAACUCC (SEQ ID NO: 24)
POL 6	5' CAGCUGGACUGUCAAUAGACAU (SEQ ID NO: 25)
POL 7	5' AACUUUCUAUGUAGAUGGGGCA (SEQ ID NO: 26)
POL 8	5' AAGGCCGCCUGUUGGUGGGCAG (SEQ ID NO: 27)
POL 9	5' UAAGACAGCAGUACAAAUGGCA (SEQ ID NO: 28)---

Page 23, please replace the second full paragraph with the following:

A3

--The HCMV/HIV-1 hybrid 3' LTR is created by recombinant PCR with three PCR primers (Figure 2). The first round of PCR is performed with RIB1 and RIB2 using pH4 (Kim *et al.*, 1998) as the template to amplify the HIV-1 HXB2 sequence 8900-9123. The second round of PCR makes the junction between the 4' end of the HIV-1 U3 and the HCMV promoter by amplifying the hybrid 5' LTR from pH4. The PCR product from the first PCR reaction and RIB3 serves as the 5' primer and 3' primer respectively.

RIB1: 5' CAGCTGCTCGAGCAGCTGAAGCTTGCATGC 3' (SEQ ID NO: 29)

RIB2: 5' GTAAGTTATGTAACGGACGATATCTTGTCTTCTT 3' (SEQ ID NO: 30)

RIB3: 5' CGCATAGTCGACGGGCCCCGCGGCTAGAGATTTTC 3' (SEQ ID NO: 31)---

Please replace the paragraph bridging pages 27 and 28 with the following:

--Egs 1/1A (SEQ ID NO. 5)

(SEQ ID NO: 5) 5'-tcgagcccggggatgacgtcatcgacttcgaaggttcgaatccttctactgccaccattttt  
cgggcccctactgcagtagctgaagctccaagcttaggaagatgacggttggtaaaaaa  
ctctacgtcatcgacttcgaaggttcgaatccttcctgtccaccagtcgacc-3'  
gagatgcagtagctgaagctccaagcttaggaagggacaggtggtcagctggagct-5' (SEQ ID NO: 32)

Egs 2/2A (SEQ ID NO. 6)

(SEQ ID NO. 6) 5'-tcgagtattacgtcatcgacttcgaaggttcgaatccttctagattcaccatttttaggaacg  
cataatgcagtagctgaagctccaagcttaggaagtactaagtggtaaaaaatccttgc  
tcacgtcatcgacttcgaaggttcgaatccttcagttccaccagtcgacc-3'  
agtagctgaagctccaagcttaggaaggtcaaggtggtcagctggagct-5' (SEQ ID NO. 33)

Egs 3/3A (SEQ ID NO. 7)

(SEQ ID NO. 7) 5'-tcgaggccaacgtcatcgacttcgaaggttcgaatccttcttcccaccatttttttcc  
ccggttgtagtagctgaagctccaagcttaggaagagaaggggtggtaaaaaaaagg  
ctgaacgtcatcgacttcgaaggttcgaatccttctgctgtcaccagtcgacc-3'  
gacttgtagtagctgaagctccaagcttaggaagacgacagtggtcagctggagct-5' (SEQ ID NO. 34)

Egs 4/4 (SEQ ID NO. 8)

(SEQ ID NO. 8) 5'-tcgagggtacgtcatcgacttcgaaggttcgaatccttctgcttcaccattttt  
cccgatgcagtagctgaatgctccaagcttaggaagaacgaagtggtaaaaaa  
ctgaacgtcatcgacttcgaaggttcgaatccttctgctgtcaccagtcgacc-3'  
gacttgtagtagctgaagctccaagcttaggaagacgacagtggtcagctggagct-5' (SEQ ID NO. 35)

Egs 5/5A (SEQ ID NO. 9)

A4  
cont

(SEQ ID NO. 8) 5'-tcgagtataacgtcatcgacttcgaaggttcgaatccttcaccgggtcaccattttttata  
catattgcagtagctgaagcttccaagcttaggaagtggccagtggttaaaaaaatat  
acgtcatcgacttcgaaggttcgaatccttctttacaccagtcgacc-3'  
tcgagtagctgaagcttccaagcttaggaagaagaatgtgggtcagctggagct-5' (SEQ ID NO. 36)

Egs 6/6A (SEQ ID NO. 10)

(SEQ ID NO. 10) 5'-tcgaggtacacgtcatcgacttcgaaggttcgaatccttcgtagttcaccattttttgtgc  
ccatgtgcagtagctgaagcttccaagcttaggaagcatcaagtggtaaaaaaacacg  
acgtcatcgacttcgaaggttcgaatccttctaggcccaccagtcgacgcatgcc-3'  
tcgagtagctgaagcttccaagcttaggaagatccgggtgggtcagctgcgtacggagct-5' (SEQ ID NO. 37) —

**REMARKS**

Formal examination of this application is respectfully requested.

Figures 3-6 and 9-13 and the specification were amended to recite sequence ID numbers for the listed sequences.

As the foregoing amendments do not introduce new matter, entry thereof by the Examiner is respectfully requested.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741.